Member Info for one4one

10 mill cash runway sorted until next year is the substance s/cap bio dream off 🐭

Now the manufacturing tech has been transferred Ai/robotic assistance should speed up the process but not until it has been tested on the humanised mice before given the green light, saying that HG-CT-1 is Autologous and can not be scaled up, so further delays for each new entrants joining the 1B cohort the science says Maybe the Market says Eventually 🐭

Oh yes bp have the data lets turn back the hands of time the lupus platform the collaboration folded & further a field orgenesis by-passed hemo car-t and collaborated with a private harley street cell therapy/ eli-lily now hemo pays them oh dear painfully reading, the average c/t is 7/8 years hemo are well behing schedule give them another 18 months to produce the jewels 🐭

I care not for your opinion phase 1 was based on safety show me the clean data so politely jog-on or scroll-on bye or better filter saves replying to your dribble🐭

Forget bp until the data comes clean 🐭

The info is out there you can read numerous papers that differ aml is still not proven and the research is evolving is the HG-CT-1 the antidote that i do not know as the c/t is in the early stage so until a update of efficacy/Mrd resistance then its a case of no-mans-land

The replys are taken from the archives of my research also condensing a scientific post in to laymans terms is for the assistance of the forum, actually refreshing from your sermons jhfh oh btw GWMO is on the move lol :-))) 🐭

Cellular killing overall, because healthy cells are spared.

Potentially equal or greater tumor-cell killing efficiency, because activation is focused on the intended malignant target.

Often reduced non-tumor inflammatory amplification, which may reduce CRS severity relative to a broadly reactive construct — though severe CRS can still occur if tumor killing is rapid and extensive.

This is one reason AML CAR-T/TCR development has been difficult: many AML antigens (e.g., CD33, CD123) are shared with normal myeloid progenitors, so potent activity can produce both effective leukemia clearance and major inflammatory/toxic hematopoietic effects simultaneously cellular killing overall, because healthy cells are spared.

Potentially equal or greater tumor-cell killing efficiency, because activation is focused on the intended malignant target.

Often reduced non-tumor inflammatory amplification, which may reduce CRS severity relative to a broadly reactive construct — though severe CRS can still occur if tumor killing is rapid and extensive.

This is one reason AML CAR-T/TCR development has been difficult: many AML antigens (e.g., CD33, CD123) are shared with normal myeloid progenitors, so potent activity can produce both effective leukemia clearance and major inflammatory/toxic hematopoietic effects simultaneously my previous reply was condensed i hope this broadens the out-look 🐭

A highly tumour-specific T-cell should produce more efficient AML killing with less collateral damage to healthy cells. That doesn’t necessarily eliminate CRS — rapid tumour killing itself can still drive IL-6/IFN-γ release — but it should improve the therapeutic window versus a construct with significant on-target off-tumour activity. Dyor 🐭

For a first-in-peadriactrics AML CAR-T like HG-CT-1, regulators and DSMBs will likely pay very close attention to:

paediatric ICANS incidence,

developmental neurocognitive trajectories,

school/learning function over time,

EEG abnormalities,

inflammatory biomarkers.

That is especially true once they escalate dose levels.

The reason paediatrics gets extra scrutiny is:

developing neural networks are more vulnerable,

cytokine surges can transiently affect brain signalling,

some effects may only emerge later in learning/executive function,

prior chemo/radiation may already have affected cognition.

paediatric CAR-T trials, there is increasing focus on baseline and longitudinal neurocognitive testing because children’s brains are still developing and clinicians want to detect subtle effects from ICANS (immune effector cell-associated neurotoxicity syndrome 🐭

The bees are buzzin' in the tree....To make some honey just for me

Look for the bare necessities, The simple bare necessities of life will come to you

That's why a bear can rest at ease & tease you🐭

Https://removepaywalls.com/

by-pass pay to read

The first three patients receive half dosage " Some CAR-T trials can include split dosing or repeat infusions, but unless the protocol specifically says so !

my bad the fluffy rns did not confirm either,...."the half dose is a safety exercise," the low-dose cohort alone is not enough to prove success either 🐭

Ok car-t therapy is not a case of rolling up the sleeves and having a infusion.

A cohort is not the patient it is a medical term used for phase 1/1b phase 2 on going as the clinical trial progresses.

the clinical trial programme is now advancing to cohort 1/b Adult escalating to to full dosage ,Autologous HG-CT-T

Whats progressing presently : recruitment...screening....eligibility

Confirm AML is relapsed/refractory.

Confirm tumour cells express FLT3 target antigen.

Assess organ function:

heart (ECG/echo),

liver,

kidneys,

lungs.

Infection screening:

hepatitis,

HIV,

CMV/EBV etc.

Bone marrow biopsy and flow cytometry.

Baseline disease burden / MRD measure/me

Leukapheresis: the patients T-cells collected from Blood..... followed by Pre-conditioning / lymphodepletion...3/5 days before infusion

fludarabine. Cyclophosphamide. for the purpose of Purpose: suppressing existing immune cells, creating "Space" for car-t expansion/improves persistence. followed by baseline safety checks for cytokine/neurological / coagulation./infection monitoring before HG-CT-1 Iv infusion / the first 7/28

days is the high risk period for CRS (cytokine release syndrome...ICANS neurotoxicity,....macrophage activation...marrow aplasia...infections.

At this point One thing worth watching closely in the upcoming higher-dose cohort: persistence of CAR-T cells...marrow recovery time/duration of MRD negativity....whether patients need stem-cell rescue afterwards....Bridging therapy (often needed in AML...Because AML progresses quickly, patients often receive interim chemo while waiting for CAR-T manufacture.

Bridging therapy (often needed in AML Because AML progresses quickly, patients often receive interim chemo while waiting for CAR-T manufacture AML CAR-T is harder than B-cell malignancies because disease burden can explode during manufacture window

Manufacturing : has been transferred "Made Tech" AI/Robotic assistance time frame i do not know ? though my understanding the tech may be more swiftly avoiding the critical control points mentioned....T cells are activated and genetically modified with the anti-FLT3 CAR construct./ Cells expanded to target dose. Quality control testing begins here :sterility/viability/transduction "Efficacy" / potency /replication -virus testing / identity confirmation.

paediatric CAR-T trials...focus on on baseline and longitudinal neurocognitive testing because children’s brains are still developing and clinicians want to detect subtle effects from ICANS (immune effector cell-associated neurotoxicity syndrome).

i will not go further the snippets are from my research: Condom if that is Gobblygook as you slam i counter claim you picked up my signal but your sat-nav needs fine tunning DYOR 🐭

s.

Https://icecool.substack.com/p/ava6103-a-multi-billion-dollar-preclinical?r=58tk8w&utm_medium=ios&triedRedirect=true

https://storage.googleapis.com/avacta-analysis/avacta_deep_research.html

May i highlight it was mentioned on this forum that hemo was scaling down the cash burn by contracting to made tech for manufacturing "seems feasible

then mentioned hemo was scaling down the lab floor space "sub-letting ?

The post below threw the forum into confusion so this post balanced the wobbly crew

The new patients entering the next cohort at the escalated dose, not the original 3 being re-dosed upward. The updates specifically say:

“the trial will now proceed to the next planned dose cohort” the original three patients will be monitored for safety....progression....duration ....survival

ok are you ready for your next assignment 🐭

October 2025, the independent Data Safety Monitoring Board ("DSMB") overseeing the trial reviewed the safety data from all three patients treated at the lowest dose level and recommended that the study proceed with escalation to the second dose level. This is a significant inflection point: it is an external, independent endorsement that HG-CT-1 has an acceptable safety profile at the starting dose, and it opens the path to the dose levels at which meaningful efficacy is most likely to emerge. The DSMB simultaneously authorised the initiation of paediatric enrolment at the same starting dose used in adults.

so the above confirms phase 1 adults half dose phase 1b escalating to full dose this will enable efficacy data across several patients not just one,

The DSMB simultaneously authorised the initiation of paediatric enrolment at the same starting dose used in adults ."Half dose" escalating to full dose🐭

the above is what i posted strange the puppies that have me filtered read my posts bottom line "curtain twitchers 🍒

Scroll back to my post i never said the original 3 patients on half dose will go forward to full dose tenantry miss read and twisted my words "plonker 🐭

The new patients entering the next cohort at the escalated dose, not the original 3 being re-dosed upward. The updates specifically say:

“the trial will now proceed to the next planned dose cohort” the original three patients will be monitored for safety....progression....duration ....survival

ok are you ready for your next assignment 🐭